Glucox Biotech AB Glucox Biotech AB is a privately owned Stockholm based Swedish research company. On the basis of a favourable patent position, extensive experience in the development of medicines for metabolic diseases, and in collaboration with academic researchers and contract research organisations Glucox Biotech develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. Management Erik Walum, PhD. CEO. Erik Walum is a former professor of Neurotoxicology at Stockholm University and has served as Head of Molecular Biology and Genomics at Pharmacia and Head of Obesity Pharmacology at Biovitrum. Mona Wilcke, PhD. CSO and founder of Glucox Biotech. Mona Wilcke has a broad experience in business development as well as research in the metabolic and diabetes field. She has been working at several biotech and large pharmaceutical companies, among them Pharmacia. She is the Chairman of the Board of Directors of Glucox Biotech AB. Per Wikström, PhD and founder of Glucox Biotech. Per Wikström has many years of research experience in the pharmaceutical industry from Immunex in Seattle, Pharmacia and Pfizer, mainly in the field of metabolic disorders and projects related to insulin resistance.
| 
